Patients with severe ITP will be randomly assigned to three groups: rhTPO group, Herombopag Group, Herombopag combined with rhTPO group. The effective rate of treatment, the rate and amplitude of platelet increase, the response time of platelet maintenance, and the effect of combination therapy on hemostasis will be compared. At the same time, the investigators will analyze the markers of thrombosis and thrombotic events to assess the safety of combination therapy.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Male or female,70 ≥age≥18;
2. Diagnosed as primary immune thrombocytopenia;
3. Platelet count was less than 10 × 10E9 / L with active bleeding, or bleeding score ≥ 5 points;
4. No use of IVIG, Avatrombopag, Eltrombopag or Romiplostim 2 weeks before treatment;
5. Rituximab was used for at least 2 months, and other immunosuppressants were stable for at least 4 weeks.
6. There was no history of platelet transfusion one week before treatment.
You may not be if
1. Secondary thrombocytopenia caused by other autoimmune diseases and virus infection was excluded;
2. Patients with active malignant tumors, pregnancy, severe cardiovascular, cerebrovascular diseases and a history of arteriovenous thrombotic diseases were excluded;
3. Patients deemed unsuitable for enrollment by the investigator;
4. Patients with thrombotic disease or serious uncontrolled cardiovascular and cerebrovascular disease;